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ImmunityTreatment with HIV attachment inhibitors (AIs) can select for escape mutants throughout the viral envelope.
We report on three such mutations: F423Y (gp120 CD4 binding pocket) and I595F and K655E (gp41
ectodomain). Each displayed decreased sensitivity to the AI BMS-488043 and earlier generation AIs, along
with increased sensitivity to the broadly neutralizing antibodies 2F5 and 4E10, without affecting the rate of
viral entry or sensitivity to the entry inhibitors AMD-3100 and Enfuvirtide. We also observed that I595F did
not substantially increase envelope sensitivity to HIV-infected patient sera. Based on these observations, we
propose that although F423Y, I595F and K655E may all affect the presentation of the 2F5 and 4E10 epitopes,
natural immune mimicry is rare only for the I595F effect. Thus, it seems that in addition to restricting AI
resistance development, incorporation of I595F into an appropriate vehicle could elicit a novel antiviral
response to improve vaccine efﬁcacy.der).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The HIV envelope is located on the virion surface and is constantly
subjected to host immune selection pressure, as it is the target of the
majority of circulating HIV neutralizing antibodies present in infected
patient sera (Li et al., 2009). Natural selection drives HIV to constantly
evolve to evade the host immune response (Parren et al., 1999;
Watkins et al., 1996), aided by the ﬂexible and heterogeneous nature
of the envelope, a thick carbohydrate shield, and hidden, discontin-
uous epitopes (Kwong et al., 1998). All of these characteristics not
only present a high hurdle in the maintenance of an effective host
immune response, but also a challenge in designing an effective,
broad-spectrum vaccine. Although patient sera have been shown to
neutralize autologous and/or heterologous virus (Deeks et al., 2006;
Parren et al., 1999), only a handful of broadly reactive neutralizing
antibodies have been identiﬁed (Burton et al., 1994; Haynes and
Monteﬁori, 2006). Strategies to induce the exposure of cross-reactiveneutralizing antibody epitopes would therefore greatly enhance the
chances for the success of a humoral vaccine design (Montero et al.,
2008; Zhang and Dimitrov, 2007; Zhang et al., 2004b,c).
HIV attachment inhibitors (AIs) belong to a novel class of oral,
small-molecule HIV antiretrovirals (Guo et al., 2003; Ho et al., 2005;
Lin et al., 2003). These inhibitors bind directly to the HIV envelope
gp120 protein, block CD4 receptor binding, induce conformational
changes at CD4 and CCR5 binding regions, and interfere with
downstream entry events (Ho et al., 2005, 2006). Similar to other
classes of HIV inhibitors, drug-resistant viruses emerge after exposure
to AIs (Colonno et al., 2004; Gong et al., 2000; Larder et al., 1995; Lin et
al., 2003; Madani et al., 2004). The complexity of Env structure/
function and the allosteric nature of some forms of AI escape lead to
the postulate that AI resistance could affect susceptibility to
neutralizing antibodies or other classes of entry inhibitors (Ho et al.,
2006; Kwong et al., 1998; Sanders et al., 2008;Wyatt et al., 1998). This
hypothesis was tested using the broadly neutralizing antibodies 4E10
and 2F5 (Binley et al., 2006; Calarese et al., 2005; Nakowitsch et al.,
2005; Zhang et al., 2004c; Zhou et al., 2007; Zwick et al., 2001, 2005),
as well as the fusion inhibitor Enfuvirtide (Manfredi and Sabbatani,
2006; Wild et al., 1992) and the CXCR4 coreceptor inhibitor, AMD-
3100 (Khan et al., 2007; Schols et al., 1997). In this report, the effect of
AI-resistant mutations on the sensitivity of virus to sera from HIV-
257N. Zhou et al. / Virology 402 (2010) 256–261infected patients was examined, and the potential utility and impact
of these changes on vaccine design and therapy are discussed.
Results
Selection of F423Y, I595F, and K655E by attachment inhibitors
Attachment Inhibitors (AI) have evolved from early leads such as
BMS-313216 (Fig. 1A) to the more potent prototype BMS-378806
(Fig. 1B). However, BMS-378806 failed to achieve target exposures in
humans (unpublished observations), so BMS-488043 (Fig. 1C), with
improved in vitro antiviral activity, a longer half-life and higher
plasma concentrations in humans was developed (Alexander et al.,
2009; Wang et al., 2009). To understand the effect of AI-resistant
mutations on the immune response to envelope, BMS-313216 and
BMS-378806 were used to select virus with decreased sensitivity to
these compounds. Treatment of HIV-LAI with 60 nM (∼2× EC50) of
BMS-313216 produced a population that displayed N1000-fold
resistance (Table 1). Twenty-three independent clones were acquired
from this pool, and sequence analyses revealed that 16/23 and 15/23
clones contained I595F and/or F423Y, respectively, and that 7/23
clones contained both mutations (Table 1). Analogous experiments
with BMS-378806 selected I595F in the absence of F423Y (6/8 clones;
Table 1), as well as K655E (6/17 clones; Table 1).
Effect of F423Y, I595F, and K655E on HIV entry inhibitor sensitivity
We suspected that mutations selected by one AI would confer
resistance to another compound of this class. To test this premise
F423Y, I595F, and K655E were introduced into the LAI background in
either an envelope expression vector or a full-length infectious HIV
clone. The former was used to coat pseudoviruses that were used in a
single-cycle format in which HeLa CD4 cells served as the target. The
latter was used to generate HIV recombinants to infect MT-2 cells in a
multiple-cycle assay format. These studies showed that these
substitutions generated by treatment with earlier generation AIs
also conferred resistance to BMS-488043 in both the single- (Fig. 2A
and Table 2) and multiple-cycle (Table 3) assay formats.
Two of the mutations (I595F, and K655E) in our study reside in the
ectodomain of gp41. We reasoned that these changes could affect
envelope sensitivity to the broadly neutralizing antibodies (bNAbs)
2F5 and 4E10, the epitopes of which are also located in this region of
the envelope (Montero et al., 2008; Zwick et al., 2001). Thus,
pseudotyped viruses with these substitutions were examined for
their ability to be neutralized by 2F5 and 4E10. The single-cycle assayFig. 1. (A) BMS-313216, (B) BMS-3revealed that not only did the gp41 mutations show enhanced
neutralization sensitivity to these antibodies, but surprisingly, so did
the F423Y substitution (N30-fold effect), although it is located in the
CD4 binding pocket of gp120 (Figs. 2B and C, and Table 2).
Comparable results were obtained using the fully infectious multi-
cycle assay (Table 3).
We expanded our studies to address the question of whether the
altered sensitivities of F423Y, I595F, and K655E for BMS-488043 and
the bNAbs applied to additional HIV entry inhibitors. Experiments
with inhibitors targeting the CXCR4 coreceptor (AMD-3100) and
membrane fusion (Enfuvirtide) showed that pseudoviruses contain-
ing the gp41mutantsmaintained sensitivity that was similar to that of
wild-type LAI (Table 4). The F423Y mutant displayed an increase in
sensitivity to these inhibitors but the effect was only 2.5-fold
(Table 4), which was not comparable with the 8- to 100-fold effect
observed for increased 2F5 and 4E10 sensitivity (Table 2).
Neutralizing sensitivity of F423Y, I595F, and K655E to HIV-infected
patient sera
We next examined whether F423Y, I595F, or K655E envelopes
would have altered sensitivity to sera from HIV infected individuals.
F423Y, I595F and K655E are either rare (2/157 for K655E, 3/157 for
I595F) or absent (F423Y) among clade B isolates (http://www.hiv.
lanl.gov/content/index); one might expect no effect of these muta-
tions against AI-naive serum. To test this premise, wild-type LAI or
mutants HIV carrying the F423Y, I595F, or K655E substitutions were
evaluated against 24 heat-treated serum samples from such indivi-
duals. Surprisingly, these studies revealed that the K655E recombi-
nant displayed a N5-fold increase in sensitivity for 87.5% (21/24) of
the samples evaluated, with 42% (10/24) of the samples displaying a
N20-fold increase in sensitivity (Table 5). For F423Y, a N5-fold
elevation in neutralization sensitivity was observed for 50% (12/24)
of the samples tested, with a N20-fold increase observed for 17% (4/
24) of the samples tested (Table 5). Only the I595F recombinant had a
minimal effect on sera neutralization characteristics, displaying an
increase in sensitivity of N5-fold for just 8.3% (2/24) of the samples
evaluated (Table 5).
Cell–cell fusion mediated by the HIV envelope
To assess if these mutations could affect the rate of envelope
mediated cell entry we employed an assay that quantiﬁed Enfuvir-
tide-sensitive fusion events between calcein AM- (green) labeled
HeLa cells expressing wild-type or mutant envelope and CMTMR-78806, and (C) BMS-488043.
Table 1
Sequence of clones selected by attachment inhibitor treatment.
AI Fold
resistance
Envelope Mutation Frequency
BMS-313216 N1396 E267G/F423Y/R444K/I596F 1/23
A266V/F423Y/I595F/E620E 1/23
W96R/F423Y/E560G/I595F 1/23
D57G/D78N/T303I/S411N/F423Y/F685L 1/23
N92D/S306G/R315G/I595F/L800P/K808R 1/23
N339S/F423Y/Q509R/I595F/N816S 1/23
T31A/F423Y/I595F/G738E 1/23
S264N/F423Y/I595F 1/23
V68A/T303I/S398N/A541T/I595S 1/23
F93L/Q203R/N301K/F423Y/I595F 1/23
F423Y/I595F 1/23
F175L/S306G/S387P/S398G/I595F 1/23
F423Y/S546P/R740G/R848S 1/23
E32K/V68A/T303I/Q352R/A541T/I595F 1/23
V84I/F423Y/A541T 1/23
L21P/N80D/E171K/A224V/F317L/
F423Y/I595F
1/23
V68A/I595F 1/23
E153G/M301K/L342V/I595F 1/23
S306G/F423Y/S546P 1/23
E106K/L125F/S546P 1/23
T303I/S334N/F423Y/A541T/D741G 1/23
A137T/S306G/G324R/I595F 1/23
F423Y/P470S/I595F 1/23
BMS-378806 1941 T303A/M434I/I595F/E648G 1/8
Y61H/N301K/L349I/G441R/I595F/S813G 1/8
I595F 1/8
M434I/C837Y/A839V 1/8
M434I/I595F/V698A/R846G 1/8
L86M/M434I/C445Y/Q507R/I595F 1/8
G152E/I165M/I595F/K655R 1/8
M434I/R469G/R542G/I595F 1/8
BMS-378806 169 L116P/S440R/K655E 1/17
V68A/S164G/T140I/G366E/M426L 1/17
V68A/G152E/M426L/Q562R 1/17
M426L/A607T 1/17
V68A/S195R/M426L 1/17
G152E/S334R/F376L/F383S/M434I/
S767N/I777V/N816S
1/17
E351K/M426L/S440R/S767G 1/17
L21P/V68A/M426L/T569A/H842R 1/17
V68A/M426L/S440R/T605I/K655E/
Δ822-823
1/17
E351K/M426L/M434I/L523S/K655E/I830V 1/17
V68A/S142N/M426L/K655E 1/17
E351K/M426L/M434I/A612T/I684M/
R696G/L765R
1/17
V68A/E351K/M426L/M434V/V506M 1/17
V68A/F175L/M426L 1/17
V68A/D107N/S144N/M434V/K655E 1/17
V68A/M434V/K655E 1/17
V68A/E351K/M426L 1/17
Fig. 2. Inhibition of HIV pseudoviruses entry. Pseudovirions coated with wild-type (open
squares)] envelopes treated with (A) BMS-488043, (B) 2F5, and (C) 4E10. Error bars have be
with nonlinear regression analysis using Prism software.
Table 2
HIV pseudovirus sensitivity to BMS-488043 and bNAbs. The values summarize the data
in Fig. 2. Values differing from WT by N5-fold are in bold.
Virus BMS-488043 2F5 4E10
EC50
(nM)
STD Fold
WT
EC50
(µg/ml)
STD Fold
WT
EC50
(µg/ml)
STD Fold
WT
WT 0.98 0.20 1.88 0.32 9.29 1.44
F423Y 10.9 1.65 11 0.06 0.01 0.03 0.72 0.09 0.08
I595F 19.0 4.47 19 0.22 0.03 0.12 0.27 0.06 0.03
K655E 6.06 0.96 6 0.02 0.01 0.01 0.22 0.05 0.02
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events (which served as a model for HIV entry) were identiﬁed by
altered ﬂuorescence (orange, Fig. 3), allowing their rate of appearance
to be quantiﬁed. These analyses revealed that in comparison to
cultures expressing wild-type LAI treated with Enfuvirtide (back-
ground nonspeciﬁc fusion), wild-type LAI and the mutant envelopes
induced a similar multiple over the frequency of nonspeciﬁc events
(Table 6). Moreover, the levels of fusion prevalence were also
comparable for these different envelopes (Table 6). From these data,
we conclude that the mutations do not substantially affect the rate of
HIV entry into cells and that such a mechanism could not explain the
observed level of sensitivity to the bNAbs.
Discussion
The envelope coats HIV particles and consequently, is the primary
target of humoral immunity. HIV vaccine strategies aimed at eliciting
antibodies that can neutralize a broad range of HIV sequences have
been unsuccessful. Thus, novel approaches that could increase the
prospects of eliciting effective immunity are indicated. We sought to
test if mutations selected by AIs could alter the conformation of the
envelope to increase the sensitivity to bNAbs, and potentially, the
immunogenicity of vaccine vectors that incorporated thesemutations.
In characterizing such mutations, it was surprising that these
compounds selected for I595F and K655E, which are located in the
ectodomain of gp41 (Table 1), since AIs dock in the CD4 binding
pocket (Ho et al., 2006). Equally surprising was our observation that
like 1595F and K655E, the F423Y mutant, residing in an area of gp120
proximal to the CD4 binding cavity (Chen et al., 2005a,b), increased
sensitivity to the bNAbs 2F5 and 4E10 (Fig. 2; Tables 2 and 3). These
ﬁndings highlight the complex nature of envelope structure/function
and suggest that the development of AI resistance in treated patients
could be restricted by speciﬁc host immune responses. This is
consistent with recent reports in which sequence changes in the
envelope that confer resistance to other HIV entry inhibitors can
increase the accessibility of some neutralizing antibody epitopes (Hu
et al., 2007; Pugach et al., 2008; Reeves et al., 2005; Vermeire et al.,circles) or mutant [F423Y (ﬁlled squares), I595F (ﬁlled triangles), and K655E (open
en omitted for clarity (the data are summarized in Table 2). Curve ﬁtting was performed
Table 3
Whole HIV sensitivity to BMS-488043 and bNAbs. Values differing from WT by N5-fold
are in bold.
Virus BMS-488043 2F5 4E10
EC50
(nM)
STD Fold
WT
EC50
(µg/ml)
STD Fold
WT
EC50
(µg/ml)
STD Fold
WT
WT 0.13 0.07 2.96 1.38 1.78 0.50
F423Y 1.15 0.65 8 0.20 0.03 0.1 0.20 0.09 0.1
I595F 0.74 0.28 6 0.47 0.11 0.2 0.06 0.02 0.03
K655E 0.65 0.04 5 0.47 0.14 0.2 0.07 0.00 0.04
Table 5
Neutralizing activity of HIV-infected patient serum.
Virus Fold increase in
neutralizing sensitivity
Frequency
F423Y N20 4/24
5–20 8/24
I595F N20 0/24
5–20 2/24
K655E N20 10/24
5-20 11/24
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step in the HIV life cycle.
The increased sensitivity to 2F5 and 4E10 conferred by F423Y,
I595F, and K655E seems to be speciﬁc in that they did not increase
sensitivity to the other entry inhibitors tested (Table 4). However,
these mutations do not affect other properties of gp160, as F423Y,
I595F, and K655E do not seem to affect the rate of HIV cell entry
(Table 6), which we have modeled with a cell–cell fusion assay
(Fig. 3). Consequently, it does not seem that increased sensitivity to
bNAbs is due to extended exposure of the envelope to the bNAbs.
Instead, we favor a model in which these mutations have an effect
similar to mutations in the 2F5 and 4E10 epitopes, which also increase
sensitivity to their respective bNAb without affecting sensitivity to
Enfuvirtide (Zwick et al., 2005). It is thought that they operate by
altering the presentation of these epitopes through conformational
changes in this domain. We suspect that the mutants in our study
similarly affect 2F5 and 4E10 epitope presentation/conformation,
albeit through an allosteric mechanism. This model is consistent with
previous observations in which the presentation of the 2F5 and 4E10
epitopes is context-dependent; underscored by the limited success
that has been achieved in eliciting nAbs using 2F5 epitope mimics
(Zhang et al., 2004a).
Reinforcing the relevance of context in epitope presentation are
data showing that the sensitivity of HIV to neutralization can be
inﬂuenced by the properties of virus producer cells as well as the type
of recipient/reporter system employed to determine viral produc-
tion/entry inhibition. In particular, the use of reporter cell lines can
lead to in vitro results that do not correlate with in vivo data. To ensure
that our data were representative, we employed two distinct systems.
In one, pseudovirus was produced from 293T cells, and entry
inhibition was tested in HeLa CD4 cells in which ﬁreﬂy luciferase
expression was driven by the HIV LTR. In the other, infectious HIV
produced from the T cell line MT-2 was used to infect this same line.
The data generated from these two formats were comparable for
BMS-488043, 2F5, and 4E10 sensitivities (Tables 2 and 3), suggesting
that the observed activities are representative of effects in vivo. In
contrast, our mutants behaved differently against the bNAb 2G12 in
the two formats (data not shown), and therefore, these data were not
included in this report. Interestingly, it was the 2G12 molecule in
which issues with reporter cell lines were previously documented
(Mann et al., 2009).
Although F423Y, I595F, and K655E exhibit similar characteristics
with respect to entry inhibitor sensitivity, they had distinct proﬁles
with regards to sensitivity to AI naive HIV infected patient seraTable 4
HIV pseudovirus sensitivity to HIV entry inhibitors. Values expressed as fold change in
comparison to wild type.
Virus AMD-3100 Enfuvirtide
F423Y 0.4 0.4
I595F 1.0 1.0
K655E 1.0 1.1(Table 4). In contrast to F423Y and K655E, I595F displayed sensitivity
that was comparable to wild type LAI; only showing increased
sensitivity to 2/24 samples (Table 4), with no substantial decrease in
sensitivity for any of the patient sera (data not shown). We interpret
these data tomean that these patients, who have developed immunity
to their circulating HIV pool, have not developed immunity that
mimics the effect of this mutation. This was the anticipated outcome
for all these mutations since they are rarely seen in Clade B isolates
and since these sera are from patients that are AI naive. We cannot
provide an explanation for the unexpected behavior of F423Y and
K655E, but it does not seem that they would enhance therapeutic
immunity. On the other hand, our observations imply that inclusion of
I595F in a vaccine vehicle could induce a novel and possibly broadly
neutralizing immune response to HIV. Such a responsemight improve
the efﬁcacy of a prophylactic vaccine or might be utilized to augment
natural immunity as a therapeutic option.
Our results show that applying AI selection pressure to the viral
entry process can lead to mutations that increase envelope sensitivity
to broadly neutralizing epitopes. These speciﬁc AI selected conforma-
tions could potentially provide novel immunogenic epitopes for HIV
vaccine approaches. Moreover, the AI selected envelopes presented
here could serve as a tool to gain a better understanding of the HIV
entry process and relevant therapeutic applications.
Methods
Reagents
2F5 and 4E10 were obtained from POLYMUN Scientiﬁc Immunbio-
logische Forschung GmbH (Austria, Vienna). Sera from HIV-infected
patients were purchased from Bioreclamation Inc. (Hicksville, NY).
All samples were from patients ≥2 months off antiretroviralFig. 3.HIV envelopemediated cell–cell fusion. Calcein AM-labeled HeLa cells expressing
the HIV envelope (green, left), CMTMR-labeled HeLa cells expressing CD4 and HIV
coreceptors (red, upper right), and fused cells (orange, middle).
Table 6
Envelope-mediated cell–cell fusion.
Virus Fold over
Enfuvirtide-treated LAI
Fusion %
(20 min coculture)
Wild-type 8.37 27.1
F423Y 8.27 32.6
I595F 6.35 23.6
K655E 6.95 27.3
260 N. Zhou et al. / Virology 402 (2010) 256–261treatment. HIV entry inhibitors were prepared at Bristol Myers Squibb
(Wallingford, CT).
Attachment inhibitor resistance selection
To identify envelope changes that decrease sensitivity to an AI,
HIV-LAI was initially treated with 2× the EC50 of compound. Infected
cells were cultured until cytopathic effects were observed. At that
time, the EC50 of the resulting strain was determined as previously
described (Lin et al., 2003). If high-level resistance (N100-fold over
wild type) was observed, RT–PCR of the isolated viral RNA was
performed, and the sequence of individual clones was determined. If
high-level resistance was not attained, the concentration of AI was
increased 2- to 10-fold, and the process was repeated until high-level
resistance was observed. Mutations that appeared in N1/3 of the
clones were considered signatures of resistance.
Preparation of pseudotyped viruses and recombinant HIV
Functional HIV envelope expression plasmids were constructed by
PCR with LAI env coding regions inserted into either pCDNA or pTRE
vectors. Mutations within the envelope gene were introduced by site-
directed mutagenesis using the QuikChange Site-directed Mutagen-
esis Kit II (Stratagene, La Jolla, CA). To produce a speciﬁc HIV envelope
pseudotyped virus, the desired HIV envelope expression plasmid and
an HIV core expression plasmid [pLAI Luc (Δenv)] (Lin et al., 2003)
were cotransfected into 293T cells using the Lipofectamine reagent
(Invitrogen, Carlsbad, CA). Transfected 293T cells were incubated for
48 h, and virus was harvested. Alternatively, these mutations were
introduced into the full-length infectious HIV clone pLAI.2 (NIH AIDS
Reagent Repository, Rockville, MD) using the QuikChange Site-
directed Mutagenesis Kit II. This DNA was also transfected into 293T
cells from which infectious recombinant HIV was harvested.
HIV neutralization assay
Susceptibility to neutralization was evaluated using an envelope
pseudotyped virus infection assay. HeLa CD4 cells were seeded (104/
well) 1 day before assay in selection-free medium [Dulbecco modiﬁed
Eagle medium (DMEM) and 10% fetal bovine serum (FBS)]. LAI (wild-
type or mutant) pseudotyped virus was added to cells in the presence
of inhibitor or patient serum. After a 3-day incubation, cell-associated
luciferase activity was determined with a Luciferase Reporter Gene
Assay (Roche, Basel, Switzerland). Alternatively, an infectious HIV
assay was utilized. Virus diluted in RPMI (10% FBS) was preincubated
with 3-fold serially diluted inhibitor. After 1 hour, MT-2 cells were
added at 1:1 (vol./vol.) ratio to the ﬁnal density of 0.1 M cells/ml and
an MOI of 0.005. On day 5 after infection, the virus yield (p24, Roche)
was determined in the culture supernatant.
Cell–cell fusion assay
To assess the rate of envelope mediated entry for wild-type LAI
and recombinant envelopes containing the F423Y, I595F, and K655E
mutations, a cell–cell fusion assay was utilized (Chien et al., 2009;
Rawat et al., 2004). HeLa cells were cotransfected with pTet-Off plusand either pTRE-LAI wt, F423Y, I595F, or K655E using Lipofectamine
2000 (Invitrogen). At 24 to 48 hours after transfection, these cells
were stained with the ﬂuorescent dye Calcein AM following the
manufacturer's protocol (Invitrogen). HeLa cells that express CD4 and
HIV coreceptors were stained with CMTMR (Invitrogen). To promote
fusion between these two cell populations, cells were mixed together
at a 1:1 ratio and incubated at 37 °C to determine the rate of fusion.
Fusion events were detected using an Evotech Opera confocal imaging
system (PerkinElmer, Campbell, CA). Confocal images were analyzed,
and fusion events were quantiﬁed (based on a minimum of 300
events) using a Cell–Cell Fusion Script algorithm following the
manufacturer's recommendations (PerkinElmer).
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